- Home
- PPBT vs XXII Comparison
PPBT vs XXII Comparison
Compare PPBT & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- XXII
- Stock Information
- Founded
- PPBT 2010
- XXII 1998
- Country
- PPBT Israel
- XXII United States
- Employees
- PPBT N/A
- XXII N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- XXII Medicinal Chemicals and Botanical Products
- Sector
- PPBT Health Care
- XXII Health Care
- Exchange
- PPBT Nasdaq
- XXII Nasdaq
- Market Cap
- PPBT 6.3M
- XXII 7.0M
- IPO Year
- PPBT N/A
- XXII N/A
- Fundamental
- Price
- PPBT $2.45
- XXII $7.15
- Analyst Decision
- PPBT Strong Buy
- XXII
- Analyst Count
- PPBT 1
- XXII 0
- Target Price
- PPBT $33.00
- XXII N/A
- AVG Volume (30 Days)
- PPBT 23.8K
- XXII 42.3K
- Earning Date
- PPBT 08-15-2025
- XXII 08-12-2025
- Dividend Yield
- PPBT N/A
- XXII N/A
- EPS Growth
- PPBT N/A
- XXII N/A
- EPS
- PPBT N/A
- XXII N/A
- Revenue
- PPBT N/A
- XXII $23,869,000.00
- Revenue This Year
- PPBT N/A
- XXII $22.41
- Revenue Next Year
- PPBT N/A
- XXII $76.35
- P/E Ratio
- PPBT N/A
- XXII N/A
- Revenue Growth
- PPBT N/A
- XXII N/A
- 52 Week Low
- PPBT $2.00
- XXII $6.28
- 52 Week High
- PPBT $13.95
- XXII $2,837.04
- Technical
- Relative Strength Index (RSI)
- PPBT 47.68
- XXII 20.79
- Support Level
- PPBT $2.26
- XXII $6.81
- Resistance Level
- PPBT $2.45
- XXII $9.50
- Average True Range (ATR)
- PPBT 0.14
- XXII 1.66
- MACD
- PPBT -0.01
- XXII -0.07
- Stochastic Oscillator
- PPBT 44.12
- XXII 6.77
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.